Research & Regulatory News

Searching a Trial Name Often Finds the Wrong Trial

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Trial names used in press coverage are frequently not registered acronyms. Searching ClinicalTrials.gov for REDEFINE 4 returns REDEFINE 1, 2 and 3 and never the trial itself, which is registered as NCT06131437 with no acronym at all.

Key facts

REDEFINE 4 registration
NCT06131437
Registered acronym
None
Searching 'REDEFINE 4' returns
REDEFINE 1, 2 and 3
Reliable search
Compound names, not trial names
Site is a JS app
Use the v2 API to read records
Wrong NCT IDs found here
Three, since corrected

Why trial names mislead

A programme name like REDEFINE or TRIUMPH is a sponsor's label for a family of studies, and individual members may or may not carry it as a registered acronym. REDEFINE 1, 2 and 3 do. The head-to-head against tirzepatide does not; its registry entry has no acronym field populated at all, so a name search cannot reach it.

What to search instead

Compound names and the comparison itself. Searching for the two drugs together returns the record immediately where the trial name fails. Then confirm identity from the official title, the enrolment number and the sponsor rather than from whichever entry appeared first.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Reading the record itself

ClinicalTrials.gov is a JavaScript application, so fetching the page often returns nothing useful. The v2 API returns structured data directly: an ordinary request for a study by its NCT number gives status, phase, enrolment, dates, allocation, masking, arms and primary outcome as plain fields.

The fields worth checking every time

Overall status, because trials change state. Enrolment, because reported figures drift. Allocation and masking, because open-label is a material limitation that press coverage omits. And the primary outcome text, which states what the trial actually set out to show. For NCT06131437 it reads as confirming non-inferiority, which is the whole context for what happened.

Why this site checks obsessively

Because three NCT identifiers published here were wrong, and one of them labelled TRIUMPH-1 pointed at an orforglipron trial, a different compound entirely. Every identifier now gets resolved against the registry before publication, and every trial referenced in this batch was pulled fresh from the API rather than recalled.

The check that takes ten seconds

Open the record. Read the official title. Confirm it names the compound you expect. A plausible-looking identifier from the right sponsor in the right format can still point at the wrong molecule, and reading the title is the step that catches it.

Frequently asked questions

Why can't I find REDEFINE 4 on ClinicalTrials.gov?

It has no registered acronym. Search the compound names instead; it is NCT06131437.

Why does fetching a ClinicalTrials.gov page return nothing?

It is a JavaScript application. The v2 API returns the same record as structured data.

Which fields matter most?

Status, enrolment, allocation and masking, and the primary outcome text, which states what the trial actually set out to show.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.